BRAF V600E mutant (A375) human melanoma tumor cells were plated at a density of 2 × 105 cells/well on a 6 well plate and treated for 48 hours with complete medium supplemented with either 35 nM ixazomib, 15 nM ixazomib, 10 nM bortezomib, or 10% DMSO. The gene discussed is BRAF; the disease is melanoma.